Glucocorticoid reduction with baricitinib in rheumatoid arthritis refractory to prior therapies: a 24-week real-world analysis

IntroductionIn a real-world cohort of rheumatoid arthritis (RA) patients who were unable to discontinue glucocorticoids (GCs) despite prior therapies, we aimed to evaluate the GC-sparing effect of baricitinib (BARI) and to identify clinical factors associated with GC reduction.Materials and methodsT...

Бүрэн тодорхойлолт

Номзүйн дэлгэрэнгүй

Үндсэн зохиолчид:	Takashi Yamane, Ayaka Inoue, Noriaki Yasuda, Takahisa Ohnishi, Akira Hashiramoto
Формат:	Artigo
Хэл сонгох:	Inglês
Хэвлэсэн:	Frontiers Media S.A. 2026-03-01
Цуврал:	Frontiers in Medicine
Нөхцлүүд:	baricitinib difficult-to-treat rheumatoid arthritis glucocorticoid tapering Janus kinase inhibitor real-world study rheumatoid arthritis
Онлайн хандалт:	https://www.frontiersin.org/articles/10.3389/fmed.2026.1797242/full
Шошгууд:	Шошго нэмэх Шошго байхгүй, Энэхүү баримтыг шошголох эхний хүн болох!